General Info

TRACON Pharmaceuticals, Inc is a biopharmaceutical company that licenses, develops, and commercializes targeted therapies for cancer and age-related macular degeneration. The current pipeline takes advantage of established platform technologies to block novel pathways implicated in cancer growth and angiogenesis. These drug candidates have the potential to be well-tolerated with side-effect profiles that don't overlap with current agents, thereby allowing for early incorporation into standard of care regimens. Our mission is to become the premiere oncology and ophthalmology therapeutics company. In order to achieve this goal, our strategy is to: Grow the company on the foundation of teamwork and proven leadership, including a senior management team with a track record of success developing targeted therapeutics ; Move product candidates through the regulatory process as efficiently as possible toward worldwide marketing authorization ; TRACON has partnered with academic and commercial entities to identify drug candidates in late preclinical and early clinical development. Our expertise is in the development of drugs to treat cancer and eye diseases. In an effort to reduce the expense and risk inherent in internal drug discovery programs, the TRACON business model is to acquire exclusive worldwide rights to drug candidates that have a promising scientific and commercial rationale. We then use our development and commercial expertise to advance these molecules through the drug development process with the goal of global marketing authorization. The management team has extensive experience identifying clear clinical and regulatory pathways, strengthening and developing intellectual property ownership, and conducting preclinical and clinical development to produce meaningful biologics and pharmaceuticals that add value for patients, physicians and shareholders.